Roflumilast Cream 0.15%

DRUG5 trials

Conditions

Atopic DermatitisAtopic Dermatitis (AD)Atopic Dermatitis EczemaITCHPlaque Psoriasis

Phase 2

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

CompletedNCT03638258

Arcutis Biotherapeutics, Inc.Plaque Psoriasis

Start: 2018-09-21End: 2019-05-29Updated: 2022-09-02

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

CompletedNCT03916081

Arcutis Biotherapeutics, Inc.Atopic Dermatitis

Start: 2019-05-31End: 2019-11-04Updated: 2023-02-13

Phase 3

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

CompletedNCT04773587

Arcutis Biotherapeutics, Inc.Atopic Dermatitis Eczema

Start: 2021-01-27End: 2022-08-30Updated: 2024-10-09

Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

CompletedNCT06631170

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Atopic Dermatitis (AD)

Start: 2024-11-21End: 2025-07-13Updated: 2025-09-02

Phase 4

Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

RecruitingNCT07560618

Integrative Skin Science and ResearchAtopic Dermatitis, ITCH

Start: 2026-07-21End: 2027-08-01Target: 40Updated: 2026-08-13

JAMA Dermatology2024-09-1841 citations

641 - Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis

British Journal of Dermatology2024-08-01

Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials

SKIN The Journal of Cutaneous Medicine2024-03-18

505 - Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials

British Journal of Dermatology2024-02-012 citations

Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

SKIN The Journal of Cutaneous Medicine2024-01-16

390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)

British Journal of Dermatology2023-06-011 citations

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study

Journal of Drugs in Dermatology2023-01-0142 citations

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

American Journal of Clinical Dermatology2022-11-1210 citations

Trial of Roflumilast Cream for Chronic Plaque Psoriasis

New England Journal of Medicine2020-07-15113 citations

Roflumilast Cream 0.15%

Sponsors

Conditions

Phase 2

Phase 3

Phase 4

Related Papers